Journal of Research in Medical and Dental Science
2022, Volume 10, Issue 12, Page No: 000-000

Available Online at: www.jrmds.in
eISSN No.2347-2367: pISSN No.2347-2545

Inflammation Due to COVID-19 Infection and its Relation to Cancer

Sarthak Mendiratta, Shiv Joshi, Prashil Jumade*

Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra, India

ABSTRACT

Inflammation is regularly connected to disease development and movement. Since the phones that cause malignant growth related inflammation are hereditarily steady thus don't foster medication obstruction rapidly, tending to aggravation as a disease anticipation and treatment technique seems engaging. Numerous factors, including bacterial and viral diseases, immune system sicknesses, corpulence, tobacco smoking, asbestos openness and unnecessary liquor admission, create growth extraneous aggravation, which expands malignant growth hazard and advances dangerous movement. Disease natural or malignant growth evoked inflammation, then again, can be brought about by malignant growth starting transformations and add to threatening movement by selecting and actuating provocative cells. Immunosuppression can be brought about by both extraneous and characteristic inflammations, giving a great climate for growth arrangement. The new review builds up a connection among inflammation and the improvement of disease.

COVID-19, which is caused by SARS-CoV-2, has emerged as the deadliest outbreak to date and has now become a major public health concern. The activation of inflammatory signaling pathways and a cytokine storm produce Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. When pro-inflammatory cytokines and chemokines are released in excess, the innate immune system is disrupted. A high number of inflammatory cells are drawn to the cytokine storm, which infiltrate lung tissues and cause immunological damage. COVID-19 patients' mortality is connected to Renin Angiotensin System (RAS) dysfunction induced by ACE-2 downregulation, in addition to immune system dysregulation. Both pathways are linked to cytokine storm, which leads to increased vascular hyper permeability, edema, hyper coagulation and multi organ damage. COVID-19, caused by the SARS-CoV-2 virus, has become the deadliest outbreak to date and a major public health concern. The activation of inflammatory signaling pathways and a cytokine storm produce Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. When pro-inflammatory cytokines and chemokines are released in excess, the innate immune system is disrupted. A high number of inflammatory cells are drawn to the cytokine storm, which infiltrate lung tissues and cause immunological damage. COVID-19 patients' mortality is linked to Renin Angiotensin System (RAS) dysfunction mediated by ACE-2 down regulation, in addition to the immune system. Both pathways are linked to cytokine storm, which leads to increased vascular hyper permeability, edema, hyper coagulation and multi organ damage.

HOW TO CITE THIS ARTICLE: Sarthak Mendiratta, Shiv Joshi, Prashil Jumade, Inflammation due to COVID-19 Infection and its Relation to Cancer, J Res Med Dent Sci, 2022, 10 (12): 000-000

Corresponding author: Dr. Prashil Jumade
E-mail: pjumade@gmail.com
Received: 03-Oct-2022, Manuscript No. JRMDS-22-71932;
Editor assigned: 05-Oct-2022, PreQC No. JRMDS-22-71932 (PQ);
Reviewed: 17-Oct-2022, QC No. JRMDS-22-71932;
Revised: 19-Dec-2022, Manuscript No. JRMDS-22-71932 (R);
Published: 27-Dec-2022

INTRODUCTION

The revelation of leukocytes inside growths by Rudolf Virchow in the nineteenth century was the principal proof of a potential connection among aggravation and disease. However, generous proof that aggravation assumes a huge part in carcinogenesis has just been found somewhat recently [1].

Be that as it may, assuming aggravation becomes ongoing or goes on for a lengthy timeframe, it tends to be perilous and lead to infection. Constant inflammation has been identified with favorable to fiery cytokines, chemokine, bond particles and incendiary compounds (Figure 1) [2].



Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13:265–270.

18. Allavena P, Sica A, Vecchi A, et al. The chemokine receptor switch paradigm and dendritic cell migration: Its significance in tumor tissues. Immunol Rev 2000; 177:141–149.
19. Burke F, Relf M, Negus R, et al. A cytokine profile of normal and malignant ovary. Cytokine 1996; 8:578–585.
20. Smyth MJ, Cretney E, Kershaw MH, et al. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202:275–293.
21. Naylor MS, Stamp GW, Foulkes WD, et al. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993; 91:2194–2206.
22. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008; 29:1275–1288.
23. Vidal Vanaclocha F, Fantuzzi G, Mendoza L, et al. IL-18 regulates IL-1 beta dependent hepatic melanoma metastasis *via* vascular cell adhesion molecule-1. USA. Proc Natl Acad Sci 2000; 97:734–739.
24. Hassuneh MR, Nagarkatti M, Nagarkatti PS, et al. Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma. Leuk Lymphoma 2013; 54:827–834.
25. Ahmad N, Ammar A, Storr SJ, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immunother 2018; 67:537–549.
26. Negus RP, Stamp GW, Relf MG, et al. The detection and localization of Monocyte Chemo attractant Protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995; 95:2391–2396.
27. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51:207–229.
28. Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 2000; 67:53–62.
29. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355:248–250.
30. Thun MJ, Namboodiri MM, Calle EE, et al. Jr aspirin use and risk of fatal cancer. Cancer Res 1993; 53:1322–1327.
31. Zhao X, Xu Z, Li H. NSAIDs use and reduced metastasis in cancer patients: Results from a meta-analysis. Sci Rep 2017; 7:1875.
32. Acharya S, Shukla S, Acharya N. Gospels of a pandemic-A metaphysical commentary on the current COVID-19 crisis. J Clin Diagn Res 2020; 14:OA01–OA02.
33. Arora D, Sharma M, Acharya S, et al. India in "flattening the curve" of COVID-19 pandemic Triumphs and challenges thereof. J Evol Med Dent Sci 2020; 9:3252–3255.
34. Bawiskar N, Andhale A, Hulkoti V, et al. Hematological manifestations of COVID-19 and emerging immuno hematological therapeutic strategies. J Evol Med Dent Sci 2020; 9:3489–3494.
35. Burhani TS, Naqvi WM. Tele health a boon in the time of COVID-19 outbreak. J Evol Med Dent Sci 2020; 9:2081–2084.
36. Butola LK, Ambad R, Kute PK, et al. The pandemic of 21st century COVID-19. J Evol Med Dent Sci 2020; 9:2913–2918.
37. Dhok A, Butola LK. Anjankar A, et al. Role of vitamins and minerals in improving immunity during COVID-19 pandemic-A review. J Evol Med Dent Sci 2020; 9:2296–2300.
38. Gawai JP, Singh S, Taksande VD, et al. Critical review on impact of COVID-19 and mental health. J Evol Med Dent Sci 2020; 9:2158–2163.
39. Khubchandani SR, Dahane TM. Emerging therapeutic options for COVID-19. J Evol Med Dent Sci 2020; 9:3082–3085.
40. Kolhe S, Dambhare M, Dhankasar P, et al. Home remedies during COVID pandemic lockdown. J Evol Med Dent Sci 2020; 8:103–107.
41. Pate BS, Yeola ME, Gawande A, et al. Best practices for endoscopic procedures in COVID-19 pandemic. J Evol Med Dent Sci 2020; 9:3760–3766.